MAP2K7 and melanoma: This led to the combination of BRAF and MEK inhibitors in clinical trials, which showed a significant improvement in overall survival compared with single-agent therapy, and subsequently FDA-approved treatment for advanced BRAFV600E-positive melanoma (35, 36).